Insomnia is a common clinical condition characterized by difficulty initiating or maintaining sleep, or non-restorative sleep with impairment of daytime functioning. Currently, treatment for insomnia involves a combination of cognitive behavioral therapy (CBTi) and pharmacological therapy. Among pharmacological interventions, the most evidence exists for benzodiazepine (BZD) receptor agonist drugs (GABAA receptor), although concerns persist regarding their safety and their limited efficacy. The use of these hypnotic medications must be carefully monitored for adverse effects. Orexin (hypocretin) neuropeptides have been shown to regulate transitions between wakefulness and sleep by promoting cholinergic/monoaminergic neural pathways. This has led to the development of a new class of pharmacological agents that antagonize the physiological effects of orexin. The development of these agents may lead to novel therapies for insomnia without the side effect profile of hypnotics (e.g., impaired cognition, disturbed arousal, and motor balance difficulties). However, antagonizing a system that regulates the sleep-wake cycle may create an entirely different side effect profile. In this review, we discuss the role of orexin and its receptors on the sleep-wake cycle and that of orexin antagonists in the treatment of insomnia.
Download full-text PDF |
Source |
|---|---|
| http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3872321 | PMC |
| http://dx.doi.org/10.3389/fphar.2013.00163 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Meta-narrative review: the impact of music therapy on sleep and future research directions.
Front Neurol
January 2025
Art Healing and Cognitive Science Research Center, Department of Music, School of Arts and Design, Yanshan University, Qinhuangdao, China.
Sleep is essential to human health, yet 27% of the global population suffers from sleep issues, which often lead to fatigue, depression, and impaired cognitive function. While pharmacological treatments exist, non-pharmacological approaches like music therapy have shown promise in enhancing sleep quality. This review, analyzing 27 studies with various experimental paradigms, confirms that music therapy significantly improves subjective sleep quality, largely by alleviating anxiety and regulating mood through perceptual pathways.
View Article and Find Full Text PDFMelatonin: A Review of the Evidence for Use in Hospital Settings.
Pharmacol Res Perspect
February 2025
Medication Safety (Formulary) Clinical Excellence Commission, Sydney, New South Wales, Australia.
New onset insomnia is often experienced by patients during hospitalization due to environmental disruptions, pain and increased patient care activities. Patient distress arising from poor sleep quality and quantity often results in the prescribing of hypnotics. Melatonin use in hospital settings is common and is increasingly used for off label indications including primary insomnia in those aged < 55 years, prevention of delirium and to facilitate benzodiazepine discontinuation.
View Article and Find Full Text PDFCross-Cultural Adaptation and Validation of the Central Sensitization Inventory Into Simplified Chinese.
Pain Manag Nurs
January 2025
School of Nursing, Shanghai Jiao Tong University, Shanghai, China. Electronic address:
Purpose: To translate the Central Sensitization Inventory from English into simplified Chinese (CSI-sC) and test the psychometric properties of the CSI-sC in patients with chronic pain.
Design: A cross-sectional design was used.
Methods: Cross-cultural adaptation of the CSI-sC was performed following Beaton's guidelines.
Insomnia in Patients With Substance Use Disorders: Assessment and Management.
J Psychiatr Pract
January 2025
Department of Psychiatry and Behavioral Sciences, Emory University, Atlanta, GA.
Insomnia, characterized by difficulty initiating or maintaining sleep, or poor sleep quality, is highly prevalent among individuals with substance use disorders (SUDs). The relationship between the 2 conditions is often bidirectional. We reviewed the impact of various substances (alcohol, stimulants, opioids, and cannabis) on sleep architecture and their potential to contribute to insomnia.
View Article and Find Full Text PDFEffectiveness of app-based cognitive behavioral therapy for insomnia on preventing major depressive disorder in youth with insomnia and subclinical depression: A randomized clinical trial.
PLoS Med
January 2025
Li Chiu Kong Family Sleep Assessment Unit, Department of Psychiatry, Faculty of Medicine, The Chinese University of Hong Kong, Shatin, Hong Kong SAR, China.
Background: Increasing evidence suggests that insomnia plays an important role in the development of depression, supporting insomnia intervention as a promising approach to prevent depression in youth. This randomized controlled trial evaluated the effectiveness of app-based cognitive behavioral therapy for insomnia (CBT-I) in preventing future onset of major depressive disorder (MDD) in youth.
Methods And Findings: This was a randomized, assessor-blind, parallel group-controlled trial in Chinese youth (aged 15-25 years) with insomnia disorder and subclinical depressive symptoms.
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!